Research Papers

25 of 751 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Association of CD209 (DC-SIGN) rs735240 SNV with paucibacillary leprosy in the Brazilian population and its functional …
Germano GV; Braga AF; Camargo RM; Ballalai PB; Bezerra OC; Manta FSN; Belone AFF; Soares CT; Das PK; Moraes MO; Latini ACP; Brito de Souza VN.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
The scientific publication of the Memórias do Instituto Oswaldo Cruz (1909-2020): a history of contribution to the biom…
Mota FB; Braga LAM; Cabral BP; Lopes RM; Alves LA.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
1/6 Transparent
Pathophysiology and new targets for therapeutic options in Chagas heart disease.
Ferreira JMBB.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
1/6 Transparent
Revisiting Chagas' disease diagnostic strategies in light of different scenarios of Trypanosoma cruzi infection.
Britto CC.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
1/6 Transparent
Air in the tires: towards an achievable, efficacious and timely diagnosis for Chagas disease.
Angheben A.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
1/6 Transparent
Different profiles and epidemiological scenarios: past, present and future.
Gorla DE; Xiao-Nong Z; Diotaiuti L; Khoa PT; Waleckx E; Souza RCM; Qin L; Lam TX; Freilij H.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
2/6 Transparent
Data
Homozygotes NAT2*5B slow acetylators are highly associated with hepatotoxicity induced by anti-tuberculosis drugs.
El-Jaick KB; Ribeiro-Alves M; Soares MVG; Araujo GEF; Pereira GRC; Rolla VC; Mesquita JF; De Castro L.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Emerging and reemerging forms of Trypanosoma cruzi transmission.
Shikanai Yasuda MA.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
2/6 Transparent
Funding Declared
First report and genome sequencing of SARS-CoV-2 in a cat (Felis catus) in Colombia.
Botero Y; Ramírez JD; Serrano-Coll H; Aleman A; Ballesteros N; Martinez C; Muñoz M; Calderon A; Patiño LH; Guzman C; Castañeda S; Hererra Y; Mattar S.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
2/6 Transparent
Trypanosoma cruzi and Chagas disease: diversity, progress and challenges.
Miles MA.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
1/6 Transparent
Peeking into the mysterious world of Trypanosoma cruzi and Chagas disease.
Macedo AM; Pena SD.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
1/6 Transparent
Trypanosoma cruzi genetic diversity: impact on transmission cycles and Chagas disease.
Zingales B; Bartholomeu DC.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
1/6 Transparent
Why do we still have not a vaccine against Chagas disease?
Camargo EP; Gazzinelli RT; Morel CM; Precioso AR.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
1/6 Transparent
Mitochondrial dysfunction on Leishmania (Leishmania) amazonensis induced by ketoconazole: insights into drug mode of ac…
Nunes DCOS; Costa MS; Bispo-da-Silva LB; Ferro EAV; Zóia MAP; Goulart LR; Rodrigues RS; Rodrigues VM; Yoneyama KAG.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Waiting for a success story in prevention, control and treatment of Chagas disease in non-endemic countries.
Bartoloni A.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
1/6 Transparent
Mapping Yellow fever epidemics as a potential indicator of the historical range of Aedes aegypti in the United States.
Fijman NS; Yee DA.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Callitrichine gammaherpesvirus 3 and Human alphaherpesvirus 1 in New World Primate negative for yellow fever virus in R…
Bonfim FFO; Mares-Guia MAMM; Horta MA; Chame M; Lopes AO; Santos R; Matias CAR; Pinto MA; de Filippis AMB; de Paula VS.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Host cholesterol influences the activity of sterol biosynthesis inhibitors in Leishmania amazonensis.
Andrade-Neto VV; Manso PPA; Pereira MG; de Cicco NNT; Atella GC; Pelajo-Machado M; Menna-Barreto RFS; Torres-Santos EC.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
1/6 Transparent
Proteolytic inhibitors as alternative medicines to treat trypanosomatid-caused diseases: experience with calpain inhibi…
Ennes-Vidal V; Dos Santos ALS; Branquinha MH; d'Avila-Levy CM.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Antileishmanial metallodrugs and the elucidation of new drug targets linked to post-translational modifications machine…
Monte Neto RLD; Moreira POL; de Sousa AM; Garcia MADN; Maran SR; Moretti NS.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Past and future of trypanosomatids high-throughput phenotypic screening.
Dantas RF; Torres-Santos EC; Silva FP.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
2/6 Transparent
Funding Declared
Perspectives for a new drug candidate for Chagas disease therapy.
Soeiro MNC.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Antioxidant defence system as a rational target for Chagas disease and Leishmaniasis chemotherapy.
Santi AMM; Murta SMF.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
2/6 Transparent
Funding Declared
Is the mitochondrion a promising drug target in trypanosomatids?
Pedra-Rezende Y; Bombaça ACS; Menna-Barreto RFS.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
1/6 Transparent
Revisiting trypanosomatid nucleoside diphosphate kinases.
Miranda MR; Sayé M; Reigada C; Galceran F; Rengifo M; Maciel BJ; Digirolamo FA; Pereira CA.
Mem Inst Oswaldo Cruz (Unknown)
Published: 2022
3/6 Transparent
Funding Declared